A New South Wales court has dealt a decisive blow to Cosette Pharmaceuticals' attempt to abandon its takeover of Mayne Pharma. The court dismissed Cosette's appeal, ruling that Mayne's weaker fiscal 2025 sales did not amount to a "material adverse change"—a legal threshold that would have allowed Cosette to walk away from the deal.
The ruling means Cosette, a U.S.-based pharmaceutical company, is now obligated to complete the acquisition it agreed to in February 2025. The decision is a significant setback for Cosette, which had argued that Mayne's financial performance had deteriorated enough to trigger a contractual escape clause.
What was the dispute about?
Cosette's attempt to terminate the deal centered on two arguments. First, it claimed that Mayne's comments about its fiscal 2025 guidance were misleading. Second, it argued that a drop in Mayne's third-quarter fiscal 2025 sales constituted a "material adverse change"—a common clause in merger agreements that allows a buyer to back out if the target's business suffers a significant, unexpected downturn.
The New South Wales Supreme Court, however, rejected both arguments. While the judge acknowledged that Mayne's sales dip was indeed an adverse change, he concluded that it was not severe enough to meet the higher "material" threshold. In legal terms, "material" is a high bar—it typically means a change that fundamentally undermines the value of the deal, not just a temporary or modest decline.
This is a classic example of how merger agreements are designed to protect buyers from genuine deterioration, but not from ordinary business fluctuations. Courts are generally reluctant to let buyers use material adverse change clauses as a convenient exit unless the impact is truly dramatic.
What happens next?
With the appeal dismissed, Cosette is legally bound to proceed with the acquisition. The company may still have options—such as appealing to a higher court—but the ruling makes it increasingly likely that the deal will close on the original terms.
For Mayne Pharma, the decision removes a cloud of uncertainty that has hung over the company since Cosette first signaled it wanted out. For Cosette, the outcome means it will have to integrate Mayne's business as planned, despite its concerns about the company's recent performance.
What it means for investors
For everyday investors, this case is a reminder that merger agreements are complex legal documents with specific conditions. When a deal is announced, the buyer's ability to walk away is not open-ended—it's limited to narrowly defined circumstances. This ruling reinforces that courts will enforce those agreements as written, even when the buyer has second thoughts.
If you hold shares in either company, the practical impact is that the deal is likely to proceed. That could mean a predictable outcome for Mayne shareholders, who may receive the agreed-upon price, but it also means Cosette shareholders will see their company take on Mayne's business and its recent sales weakness.
For investors in the broader pharmaceutical sector, this case highlights the importance of reading the fine print in any acquisition. Material adverse change clauses are standard, but they are not a free pass for buyers to renegotiate or cancel a deal simply because the target's performance disappoints.
As always, it's wise to watch how the companies proceed from here. Any further legal moves by Cosette could extend the uncertainty, but for now, the court has spoken: the deal stands.
